• 25.11.2019 – 10:13

  Jennewein Biotechnologie GmbH

  Jennewein Biotechnologie obtains US-FDA GRAS status on alternative 2'-fucosyllactose fermentation strain

  Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, Rheinbreitbach, the leading manufacturer of human milk oligosaccharides (HMOs), announces that the U.S. Food and Drug Administration (FDA) issued a "no question" response letter to Jennewein's supplement of its GRAS Notice GRN571, thereby acknowledging that the ...

  more

• 25.11.2019 – 10:02

  Jennewein Biotechnologie GmbH

  Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

  Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...

  more

• 03.01.2019 – 10:01

  ProBioGen AG

  ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

  Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...

  more

• 08.08.2018 – 18:40

  Kyowa Kirin International PLC

  Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

  Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...

  more